ferrin and iron and, therefore, the saturation of transferrin. Saturation, in turn, affects the proportions of the different molecules and so may relate absorption to iron stores. In some circumstances the proportions of saturated and halfsaturated molecules may also be affected by the activity ofthe erythropoietic marrow. Forexample the plasma of patients with ineffective erythropoiesis and a high plasma iron concentration appears to contain more half-saturated transferrin molecules than would be expected from the level of iron saturation (Fletcher 1969) . This presumably reflects the affinity of developing red cells for the saturated form of transferrin. Since the developing mucosal cells also have an affinity for saturated molecules which are removed by the marrow, they will not receive so much priming iron and iron absorption will continue out of proportion to the body's stores. Certainly patients with thalasswrmia, sickle-cell disease or hereditary spherocytosis may develop severe iron overload. Therefore, the plasma messenger may be the proportion of saturated and half-saturated transferrin molecules in the circulation and this may relate the rate of absorption to the body's iron stores and to the rate of erythropoietic activity. Dr J Fielding (St Mary's Hospital, Harrow Road, London W9)
Storage Iron and Desferrioxamine
Desferrioxamine is the most effective and specific chelator of trivalent iron. The iron chelate, the red pigment ferrioxamine, has a stability constant of 1031 at physiological pH and thus exceeds the two constants of iron transferrin. After its isolation ten years ago (Bickel et al. 1960 ), its potential use for eliminating body iron in conditions of iron overload was soon recognized. In fact, therapeutic applications have been limited, but desferrioxamine (Desferal) is now the definitive treatment for inorganic iron poisoning, which still claims children's lives, and in this application it is almost certainly life-saving.
Interest in desferrioxamine has developed mainly in clinical and experimental investigation, especially in connexion with the assessment of storage iron. Until recently the quantitative measurement of storage iron has been possible only on an experimental basis. Comparatively crude histochemical assessment can be made on biopsy material of marrow, liver or skin, using the Prussian blue reaction. Desferrioxamine, in various test procedures, has been the nearest approach so far made under clinical conditions to the quantitative measurement of whole body storage iron.
Information on total storage iron in man has been meagre. Hynes (1949) subjected himself to repeated small venesections over a long period of time until he became anemic and calculated that he had begun with 600 mg storage iron. This principle was modified by Haskins et al. (1952) using large phlebotomies over a short period. They estimated normal storage iron to be between 1,000 and 1,500 mg. Isotope dilution methods give lower results, attributable to incomplete exchange between isotope and storage iron.
The properties of ligand and chelate differ considerably. Desferrioxamine is a straight chain trihydroxamic acid (mol. wt. 597), a white solid, colourless in solution. Ferrioxamine is a red pigment, containing one-tenth of its weight of iron. Desferrioxamine enters cells easily and occupies the total body water: ferrioxamine occupies the extracellular space only and seems to be averse to an intracellular site. When ferrioxamine is formed intracellularly by the action of desferrioxamine on storage iron, it appears to move quickly out of the cell. When formed in liver parenchyma, for instance, it moves mainly into blood capillaries, but also to some extent into the biliary tract. Desferrioxamine is rapidly excreted in the urine and undergoes enzymatic degradation. As a result of these two processes its chelating activity after parenteral injection persists for only about thirty minutes. Ferrioxamine is far more stable in vivo: only 14-18% of its iron appears as hxmoglobin; it is excreted in the urine more slowly than desferrioxamine. Neither hxem iron nor transferrin iron (in vivo) give up iron to the chelator. The main source of body iron chelated by desferrioxamine is undoubtedly storage iron as ferritin; but there is also much evidence that hxem, during its catabolism, may give rise to a transient form Table I The effect of age and ha:moglobin concentration on 6-hour ferrioxamine excretion Table 1 ) which is more highly chelatable than ferritin (Karabus & Fielding 1967) .
Several clinical tests for storage iron overload have been based on a parenteral injection of a standard dose of Desferal (desferrioxamine methanesulphonate) followed by measurement of the augmented excretion of iron which follows. Useful diagnostic information may be obtained in iron overload by these procedures (Ploem et al. 1966 , Hedenberg 1969 . However, comparative quantitative data between individual subjects cannot be obtained in this way. The principal limitation of this approach is the wide variation in urinary excretion of a standard dose of ferrioxamine between different subjects; the variation extends over a ten-fold range. This variability is of the same order as the amount of storage iron in hcmochromatosis compared with normal subjects. Thus the amount of ferrioxamine iron excreted cannot reflect quantitatively the amount which is formed from in vivo chelation.
We have examined two factors, age and anaemia, which influence the urinary excretion of ferrioxamine, the preformed iron chelate, after its intravenous injection. Fig 1 shows the striking inverse relation between six-hour excretion and age in subjects with iron deficiency ancmia. A similar relationship is seen in megaloblastic anemias. It is possible that ferrioxamine excretion after intravenous injection may be a sensitive test of decreasing renal efficiency with increasing age. The presence of anemia also decreases ferrioxamine excretion (Table 1) .
The combined effect of anvmia and age accounts for 54 % of the variability between subjects. The test we devised takes these variables into ccount and is simple to carry out. The standard lose of the chelator Desferal is given intravenousy, accompanied by a standard dose of its red iron helate labelled with 59Fe. The labelled chelate is imply and quickly prepared. Urine is collected or six hours. Isotope activity in the urine gives he proportion of ferrioxamine excreted. Total errioxamine is estimated chemically: this has een derived partly from that injected and partly rom in vivo chelation. In this test endogenous helation of intracellular storage iron occurs luring the period of about one half-hour after njection to produce ferrioxamine. This joins the irculating ferrioxamine already injected while he isotope monitors its metabolic fate. By calcuation the amount of body iron chelated is ascerained. Since this test was devised, it has become nown (Gevirtz et al. 1965 ) that about one-third f iron chelated from liver parenchyma is excreted n the bile and appears in the fteces. However, ntravenously injected ferrioxamine is not excreted n the bile and does not appear in significant tmounts in the gut. Thus Fv values underestimate ,omewhat the total amount of body iron chelated )y the dose of Desferal. Nevertheless, it seems hat the proportion of biliary excretion from liver ron is constant from subject to subject and Fv talues remain a valid quantitative measure of -helatable storage iron. This is well illustrated by he relationship between variable doses of Deseral and the amount of in vivo chelation as calcuated by this method. Htemolytic *Includes some iron deficiency an.emias and compensated hsemolytics logarithm of the Desferal dose. Furthermore, the slope of the dose-response curve in all subjects tested is virtually identical: the test system is reproducible and constant between subjects. The upper four slopes are from untreated idiopathic hemochromatosis; the fifth is from a case of idiopathic pulmonary hemosiderosis. The latter case is of particular interest: the patient had a moderately severe iron deficiency anlemia; her normal storage sites were certainly depleted of iron, and the abnormal deposits of pulmonary iron are known to be in reticuloendothelial cells. Nevertheless, these deposits of ferritin and hemosiderin were as available to Desferal chelation as parenchymal stores in heemochromatosis and indeed gave the same dose-response relationship. This finding does not support the view of Harker et al. (1968) , who suggest that reticuloendothelial storage is relatively unchelatable by desferrioxamine. A factor not given sufficient consideration is the accessibility of storage sites to the action of the chelating agent. For instance, in the limited time available for chelation after a single injection, the relatively sluggish blood flow through the spleen implies less exposure of its storage iron to circulating chelators, compared for instance with stores in liver or lung. Barry et al. (1969) have shown by serial tests in hmmochromatotics undergoing venesection, that Fv values are linearly related to storage iron. Thus the differential ferrioxamine test enables storage iron to be quantified from Fv values, at least in hemochromatotics. They also show that when storage iron is above the normal range, histochemical grading is unrelated to Fv values and provides no quantitative data. They also show, confirming Smith et al. (1967) , that Fv values distinguish between cirrhotic siderosis and idiopathic heemochromatosis.
An unexpected finding has been the high Fv values in haemolytic anemias. These values are sometimes even higher than in idiopathic hemochromatosis, although the latter patients harbour many times more storage iron. This has suggested that in hemolytic conditions there is an alternative source of chelatable iron, associated with the catabolism of heem (Fielding 1965) . The changing pattern of Fv values in pernicious anaemia during vitamin B1, therapy supports such an additional source. Initially high Fv values fell rapidly during therapy before hemoglobin had much changed, in other words before storage iron had been significantly reutilized for hemoglobin synthesis. Intramedullary himolysis (ineffective erythropoiesis) is a marked feature of untreated pernicious anamia and is rapidly reversed by vitamin B,2; the rapid fall in Fv values coincident with reversal of intramedullary h2emolysis supports the view that hmem catabolism may provide a highly chelatable source of iron. A similar phenomenon is seen in some cases of iron deficiency anmemia, where Fv values are found in the range for normal men, whereas most cases have Fv values below 100 ,ug/kg. Kinetic studies (Pollycove & Mortimer 1961) have long suggested that intramedullary hemolysis is a feature of iron deficiency and here again we found that a short course of oral iron therapy quickly depressed those Fv values previously in the normal range, to the 'expected' iron deficiency range (Brunstrom et al. 1968 ). This finding would appear to be entirely analogous to the effect of vitamin B12 therapy in pernicious animia.
We have found, too, that when there is a sudden increase in the rate of hmm catabolism, as after massive soft tissue hemorrhage due to severe fractures, Fv values increase markedly over a period of some days and gradually return to normal (O'Shaughnessy et al. 1966) . Experimental support for this view also comes from studies of phenylhydrazine-treated animals. It is also of some interest that in iron deficiency anamias, in which storage iron is depleted and cannot form an important source of chelatable iron, the mean Fv value is approximately 60,g/kg as ferrioxamine.
If it is assumed that chelating activity of desferrioxamine lasts for only thirty minutes, this corresponds closely to the rate of iron release from normal hem catabolism.
The diagnostic applications of the differential ferrioxamine test are summarized in Table 2 . It is worth mentioning that whenever clinically significant renal failure has been present, recognized by high blood urea or low creatinine and vitamin B12 clearence, the percentage excretion of the 59Fe ferrioxamine label has always been less than 5 %. Conversely, in the investigation of undiagnosed anemia, excretion of less than 5 % has revealed unsuspected renal failure.
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The clinical uses of Desferal and desferrioxamine tests may be summarized as follows: 
Body Iron Loss and Cell Loss from Epithelia
In clinical practice iron deficiency is due to inadequate intake, malabsorption or excessive iron loss. The usual cause of iron loss is chronic bleeding, either from the gastrointestinal tract or because of menorrhagia. Another possible way of losing iron is via epithelial surfaces of the gut and skin. In this paper I should like to consider two aspects of this problem. Is iron lost from epithelial surfaces? Is epithelial iron loss clinically significant?
Skin Cell Turnover and Iron Loss In the skin, as in other epithelia, there is a constant renewal of epithelial cells. In man the turnover time of these cells is normally 28 days (Rothberg et al. 1961) . The cells are produced by mitosis, they migrate towards the surface, they then lose their nuclei and other intracellular constituents and are lost from the body as minute scales. In generalized exfoliative psoriasis the situation is fundamentally different for there is a high turnover of epithelial cells. The cells are produced at eight times the normal rate; the cell's life is 4 days instead of 28 days. Furthermore, the cells do not lose intracellular constituents and they are lost from the body with their nuclei intact (Fig 1) . Thus, psoriatic scales are composed of nucleated epithelial cells whereas normal skin scales contain non-nucleated cells.
When cells are lost from epithelia with their nuclei intact it is possible to quantitate this loss by measuring the amount of DNA lost (Croft & Lubran 1965). We have done this in generalized exfoliative psoriasis by collecting all the scales lost during 24 hours (Croft, Lim & Taylor 1968) . These patients lose about 20 g of skin scales per 24 hours, and these scales can be shown to be composed of nucleated cells. As there is the same quantity of DNA in each human cell, and the amount per cell is known, measurement of the rate of DNA loss can be used to estimate the number of cells lost. In generalized exfoliative psoriasis about 3 million cells are lost per minute or about 4,500 million cells per 24 hours. This may sound a lot but it is only one-twelfth of the number of cells that are normally lost into the entire gut per 24 hours.
Marks & Shuster (1968) have measured iron lost from the skin in patients with generalized exfoliative psoriasis. Their mean value was 4x1 mg/24 h; their highest value was 7-3 mg/24 h. Continued loss of iron at this rate could be a factor causing aneemia in these patients. There are, however, other factors causing anmemia in patients with exfoliative psoriasis.
Gastrointestinal Epithelial Cell Turnover andLoss In the normal gut epithelial cells are exfoliated into the lumen with their nuclei intact (Fig 2) (Pink et al. 1970) . It is therefore possible by washing segments of the gastrointestinal tract of man to obtain values for the rate of DNA loss and thus of cell loss. We have obtained values for cell loss from normal human stomach, small intestine and large intestine (Croft et al. 1966 , Croft, Loehry, Taylor & Cole 1968 , Croft & Levitan 1970 . The small intestine, which has both the highest turnover and the largest surface area, contributes 90 % of the total gut cell loss, which is
